PTC Therapeutics, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
PTC Therapeutics, Inc. (PTCT) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $27.68 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $26.82M, a 560.23% increase year-over-year.
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $850.00K, a 50.67% decline year-over-year.
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $27.68M, a 328.27% increase from fiscal 2024.
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $6.46M.
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $35.82M, a 5453.02% increase from fiscal 2021.
- PTC Therapeutics, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $645.00K, a 99.16% decline from fiscal 2020.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $26.82M derived: sum of 2 quarters · filed 2026-02-19 | $26.82M derived: sum of 3 quarters · filed 2026-07-30 | $27.68M 10-K · filed 2026-02-19 |
| 2025-09-30 | $26.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $26.82M derived: sum of 2 quarters · filed 2026-07-30 | $27.68M 10-Q · filed 2025-11-04 | $28.35M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $850.00K 10-Q · filed 2026-07-30 | $1.53M derived: sum of 3 quarters · filed 2026-07-30 | $5.59M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $850.00K 10-Q · filed 2026-05-07 | $1.53M derived: sum of 2 quarters · filed 2026-05-07 | $5.59M derived: sum of 3 quarters · filed 2026-05-07 | $5.59M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $676.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $4.74M derived: sum of 2 quarters · filed 2026-02-19 | $4.74M derived: sum of 3 quarters · filed 2026-02-19 | $6.46M 10-K · filed 2026-02-19 |
| 2024-09-30 | $4.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.06M derived: sum of 2 quarters · filed 2025-11-04 | $5.79M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.72M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $1.72M 10-Q · filed 2025-05-06 | |||
| 2022-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$32.83M derived: sum of 2 quarters · filed 2025-02-27 | $35.23M derived: sum of 3 quarters · filed 2025-02-27 | $35.82M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$33.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $34.71M derived: sum of 2 quarters · filed 2023-10-26 | $35.29M 10-Q · filed 2023-10-26 | |
| 2022-06-30 | $68.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $68.64M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $587.00K 10-Q · filed 2023-04-27 | |||
| 2021-12-31 | $645.00K 10-K · filed 2024-02-29 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $13.00K 10-Q · filed 2022-08-04 | $167.00K derived: sum of 3 quarters · filed 2023-02-21 | $58.71M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $13.00K 10-Q · filed 2022-05-03 | $167.00K derived: sum of 2 quarters · filed 2023-02-21 | $58.71M derived: sum of 3 quarters · filed 2023-02-21 | $54.18M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $58.69M derived: sum of 2 quarters · filed 2023-02-21 | $54.17M derived: sum of 3 quarters · filed 2023-02-21 | $76.81M 10-K · filed 2023-02-21 |
| 2020-09-30 | $58.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $54.02M derived: sum of 2 quarters · filed 2021-10-28 | $76.66M 10-Q · filed 2021-10-28 | $77.93M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$4.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $18.12M 10-Q · filed 2021-07-29 | $19.39M derived: sum of 3 quarters · filed 2022-02-22 | $23.86M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $22.64M 10-Q · filed 2021-05-04 | $23.91M derived: sum of 2 quarters · filed 2022-02-22 | $28.39M derived: sum of 3 quarters · filed 2022-02-22 | $28.72M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $5.75M derived: sum of 2 quarters · filed 2022-02-22 | $6.08M derived: sum of 3 quarters · filed 2022-02-22 | $17.39M 10-K · filed 2022-02-22 |
| 2019-09-30 | $4.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $4.81M derived: sum of 2 quarters · filed 2020-10-29 | $16.12M 10-Q · filed 2020-10-29 | $16.12M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $329.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $11.64M 10-Q · filed 2020-08-05 | $11.64M derived: sum of 3 quarters · filed 2020-08-05 | $11.64M derived: sum of 4 quarters · filed 2020-08-05 |
| 2019-03-31 | $11.31M 10-Q · filed 2020-04-30 | $11.31M derived: sum of 2 quarters · filed 2020-04-30 | $11.31M derived: sum of 3 quarters · filed 2020-04-30 | $11.31M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 derived: sum of 2 quarters · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |